MDM2 SNP309 and SNP354 are not associated with lung cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 8, 2006, Pages 1559-1561

  Pine, Sharon R ^a   Mechanic, Leah E ^a   Bowman, Elise D ^a   Welsh, Judith A ^a   Chanock, Stephen C ^a   Shields, Peter G ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; UNITED STATES;

EID: 33748038740     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0217     Document Type: Article

References (12)

1. Michael D, Oren M. The p53-2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
2. Arva NC, Gopen TR, Talbott KE, et al. A chromatin-associated and transcriptionally inactive p53-2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005;280:26776-87.
3. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
4. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
5. Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-7.
6. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2005.
7. Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006;118:1275-8.
8. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;119:718-21.
9. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-7.
10. Zheng YL, Loffredo CA, Yu Z, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
11. Mechanic LE, Marrogi AJ, Welsh JA, et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005;26:597-604.
12. Dupont WD, Plummer WD, Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998;19:589-601.